Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Eli Lilly stock in Canada

Learn how to buy Eli Lilly stock in 5 easy steps.

Eli Lilly is a drug manufacturers-general business based in the US. Eli Lilly stocks (LLY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $427.24 – an increase of 0.35% over the previous week. Eli Lilly employs 39,000 staff and has a trailing 12-month revenue of around $27.7 billion.

How to buy Eli Lilly stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – LLY. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Eli Lilly stock price (NYSE:LLY)

Use our graph to track the performance of LLY stocks over time.

Eli Lilly shares at a glance

Information last updated 2023-05-27.
Latest market close$427.24
52-week range$279.80 - $454.95
50-day moving average $387.29
200-day moving average $350.87
Wall St. target price$428.61
PE ratio 68.0176
Dividend yield $4.07 (1.06%)
Earnings per share (TTM) $6.26

Buy Eli Lilly and Company stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy Eli Lilly stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Eli Lilly price performance over time

Historical closes compared with the close of $427.24 from 2023-05-30

1 week (2023-05-24) 0.35%
1 month (2023-05-01) 5.28%
3 months (2023-03-03) 34.17%
6 months (2022-12-01) 15.37%
1 year (2022-05-31) 36.31%
2 years (2021-05-28) 113.90%
3 years (2020-05-29) 179.33%
5 years (2018-05-31) 402.40%

Is Eli Lilly stock undervalued or overvalued?

Valuing Eli Lilly stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly financials

Revenue TTM $27.7 billion
Operating margin TTM 27.82%
Gross profit TTM $21.9 billion
Return on assets TTM 9.62%
Return on equity TTM 54.79%
Profit margin 20.54%
Book value $12.44
Market capitalisation $405.6 billion

TTM: trailing 12 months

Eli Lilly's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Eli Lilly's total ESG risk score

Total ESG risk: 32.36

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Eli Lilly's environmental score

Environmental score: 0.63/100

Eli Lilly's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Eli Lilly's social score

Social score: 16.68/100

Eli Lilly's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Eli Lilly's governance score

Governance score: 13.31/100

Eli Lilly's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Eli Lilly's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly hasn't always managed to keep its nose clean.

Eli Lilly share dividends


Dividend payout ratio: 60.81% of net profits

Recently Eli Lilly has paid out, on average, around 60.81% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly shareholders could enjoy a 1.06% return on their shares, in the form of dividend payments. In Eli Lilly's case, that would currently equate to about $4.07 per share.

Eli Lilly's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Eli Lilly's most recent dividend payout was on 9 June 2023. The latest dividend was paid out to all shareholders who bought their shares by 12 May 2023 (the "ex-dividend date").

Have Eli Lilly's shares ever split?

Eli Lilly's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly shares which in turn could have impacted Eli Lilly's share price.

Eli Lilly share price volatility

Over the last 12 months, Eli Lilly's shares have ranged in value from as little as $279.8033 up to $454.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly's is 0.367. This would suggest that Eli Lilly's shares are less volatile than average (for this exchange).

Eli Lilly overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site